

Handbook of

---

**Pharmacokinetic/  
Pharmacodynamic  
Correlation**

*Edited by*

**Harmut Derendorf, Ph. D.  
Günter Hochhaus, Ph.D.**

*University of Florida  
Gainesville, Florida*



CRC Press

Boca Raton London Tokyo

Pharmacy Library  
University of Wisconsin - Madison  
2130 Chamberlain Hall  
425 N. Charter Street  
Madison, WI 53706-1508

Library of Congress Cataloging-in-Publication Data

Handbook of pharmacokinetic/pharmacodynamic correlation / edited by Hartmut Derendorf, Günther Hochhaus.

p. cm.

Includes bibliographical references and index.

ISBN 0-8493-8303-X

1. Pharmacokinetics. 2. Drugs—Physiological effect.

I. Derendorf, Hartmut. II. Hochhaus, Günther.

[DNLM: 1. Pharmacokinetics. 2. Pharmacology. 3. Dose-Response Relationship, Drug. 4. Models, Theoretical.

QV 38 H2365 1995]

RM301.5.H36 1995

615'.7—dc20

DNLM/DLC

for Library of Congress

94-22365

CIP

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher.

All rights reserved. Authorization to photocopy items for internal or personal use, or the personal or internal use of specific clients, may be granted by CRC Press, Inc., provided that \$.50 per page photocopied is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970 USA. The fee code for users of the Transactional Reporting Service is ISBN 0-8493-8303-X/95/\$0.00+\$.50. The fee is subject to change without notice. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

CRC Press, Inc.'s consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press for such copying.

Direct all inquiries to CRC Press, Inc., 2000 Corporate Blvd., N.W., Boca Raton, Florida 33431.

© 1995 by CRC Press, Inc.

No claim to original U.S. Government works

International Standard Book Number 0-8493-8303-X

Library of Congress Card Number 94-22365

Printed in the United States of America 1 2 3 4 5 6 7 8 9 0

Printed on acid-free paper

---

## Table of Contents

---

Chapter 1 Pharmacokinetic-Pharmacodynamic Modeling of Reversible Drug Effects .....	1
<b>Jürgen Venitz</b>	
Chapter 2 Pharmacokinetic-Pharmacodynamic Modeling of Irreversible Drug Effects .....	35
<b>Steven C. Ebert</b>	
Chapter 3 Pharmacokinetic-Pharmacodynamic Modeling in Drug Development: Comments and Applications .....	57
<b>Joseph C. Fleishaker and James J. Ferry</b>	
Chapter 4 Dose Optimization Based on Pharmacokinetic-Pharmacodynamic Modeling .....	79
<b>Günther Hochhaus and Hartmut Derendorf</b>	
Chapter 5 Pharmacokinetic-Pharmacodynamic Correlations of Anesthetic Agents .....	121
<b>Virginia D. Schmith and Keith T. Muir</b>	
Chapter 6 Pharmacokinetic-Pharmacodynamic Correlations of Analgesics .....	141
<b>Judith S. Walker</b>	
Chapter 7 Pharmacokinetic-Pharmacodynamic Correlations of Benzodiazepines .....	171
<b>Samir K. Gupta and Everett H. Ellinwood</b>	
Chapter 8 Pharmacokinetic/Pharmacodynamic Correlations of Anticonvulsants .....	185
<b>Meindert Danhof and Rob A. Voskuyl</b>	
Chapter 9 Pharmacokinetic-Pharmacodynamic Relationships of Cardiovascular Drugs .....	197
<b>Richard L. Lalonde</b>	

Chapter 10	
Pharmacokinetic/Pharmacodynamic Correlations of Selected Vasodilators .....	227
<b>Tsang-Bin Tzeng and Ho-Leung Fung</b>	
Chapter 11	
Pharmacodynamics of Anticoagulants .....	241
<b>Dennis Mungall and Richard H. White</b>	
Chapter 12	
Pharmacokinetic-Pharmacodynamic Correlations of Antihistamines .....	275
<b>Eric Snoeck, Achiel Van Peer, and Jos Heykants</b>	
Chapter 13	
$\beta_2$ -Agonists: Terbutaline, Albuterol, and Fenoterol .....	299
<b>Günther Hochhaus and Helmut Möllmann</b>	
Chapter 14	
Pharmacokinetic-Pharmacodynamic Correlations of Corticosteroids .....	323
<b>Helmut Möllmann, Stefan Balbach, Günther Hochhaus, Jürgen Barth, and Hartmut Derendorf</b>	
Chapter 15	
Pharmacokinetic/Pharmacodynamic Modeling of Antibiotics .....	363
<b>Arno Nolting and Hartmut Derendorf</b>	
Chapter 16	
Clinical Pharmacodynamics of Anticancer Drugs .....	389
<b>Howard L. McLeod and William E. Evans</b>	
Chapter 17	
Computer Applications in Clinical Pharmacokinetics and Pharmacodynamics .....	415
<b>Dennis Mungall, Joe Heissler, and Matthieu Kaltenbach</b>	
Index .....	465

## Chapter 2

# PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF IRREVERSIBLE DRUG EFFECTS

Steven C. Ebert

## INTRODUCTION

The mathematical relationship between drug concentration and response generally assumes drug binding to a given population of receptors. Greater occupation of these receptors will result in a greater effect, and vice versa. The variability in receptor affinity accounts for the nonlinear relationship between concentration and effect.

Most research involved in the characterization of pharmacodynamic variables has been done with drugs exhibiting reversible effects. With reversible drug effects, the number and drug affinity of receptors remain relatively constant, allowing reproducible effects with repeated drug exposures. In certain instances, sensitization or tolerance to the drug effect may occur.

In contrast, the goal of antimicrobial therapy is to eliminate the very target at which the drug is directed, i.e., the "receptors" are actually the pathogenic organisms. The desired effect of drug therapy, the death of pathogens, is therefore irreversible. The replication of organisms, with subsequent replenishment of the "receptor" number may occur, however, and result in an apparently reversible effect as measured by the total number of organisms. In this system, the development of tolerance or frank resistance of the remaining "receptors" is more likely to occur, since the most susceptible organisms are killed. Therefore, it would be expected that sustained exposure to an antimicrobial would result in a gradually diminishing effect over time, unless a sufficient drug-free period exists to enable the organism population to fully recover its susceptibility.

Figure 1 shows the relationship between pharmacokinetic variables, pharmacodynamic measures of antimicrobial activity, and drug effect. Intuitively, increasing the dose of an antimicrobial should increase its effect. By understanding the pharmacodynamic features of a given class of antimicrobials, one may, however, be able to further enhance outcome by modifying dosing parameters other than dose size, e.g., dosing frequency. The pharmacodynamic properties of antimicrobials may be estimated *ex vivo*, whereas for other drug classes, response must be estimated *in vivo*. This chapter will address the pharmacokinetic and pharmacodynamic properties of antimicrobials which influence drug response, will characterize drug effects, and will then examine techniques that have been used to link these phenomena.

## PHARMACOKINETIC VARIABLES

The pharmacokinetic variables of a drug determine the time course of drug concentration in serum and, ultimately, at the site of infection. Two different categories of pharmacokinetic variables exist. Some pharmacokinetic variables may be altered by adjusting the dosing regimen, whereas others result from the chemical properties of a particular drug, and are minimally influenced by dosing regimen. In the clinical setting, modification of regimen-dependent variables is the goal of pharmacokinetic therapeutic drug monitoring, in order to achieve the desired concentration profile.<sup>2-4</sup>

### REGIMEN-DEPENDENT VARIABLES

Most antimicrobials are administered intermittently, i.e., a given total daily dose is divided and the fractions given at fixed intervals. The three pharmacokinetic variables that may be used to

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.